MUC2 and hydrops fetalis: Based on this consistency, the clinical question to see if HF-MUC2 glycans can be used to detect differences in healthy versus CD we believe also accurately captured a major shift in the glycome of active CD samples, which both showed a similar increase in sialylated and/or sialylated+fucosylated glycans, and the fact that sialylation-specific SNA seemed to ready label an active CD sample.